Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -17.48% is 20% above its 5-year average of -21.92%, around the middle of its 5-year range (-69.68%–7.10%).
62.91% above its 12-month average of -47.13%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -5.95%.
RETURN ON ASSETS (ROA)
-17.48%
RETURN ON ASSETS (ROA) AVG TTM
-47.13%
RETURN ON ASSETS (ROA) AVG 3Y
-32.40%
RETURN ON ASSETS (ROA) AVG 5Y
-21.92%
RETURN ON ASSETS (ROA) AVG 10Y
-35.52%
RETURN ON ASSETS (ROA) AVG 15Y
-41.93%
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+62.91%
CURRENT VS 3Y AVG
+46.05%
CURRENT VS 5Y AVG
+20.27%
CURRENT VS 10Y AVG
+50.79%
CURRENT VS 15Y AVG
+58.31%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 855 covered companies
CURRENT VS SECTOR MEDIAN
+45.78%
vs the sector median at left
Pacific Biosciences of California, Inc.
Market Cap
$848.07M
Return on Assets (ROA)
-17.48%
TTM Avg
-47.13%
3Y Avg
-32.40%
5Y Avg
-21.92%
Market Cap
$848.38M
Return on Assets (ROA)
-18.34%
TTM Avg
-25.78%
3Y Avg
-11.37%
5Y Avg
4.46%
Market Cap
$842.52M
Return on Assets (ROA)
-23.03%
TTM Avg
-34.41%
3Y Avg
-34.41%
5Y Avg
-34.41%
Market Cap
$839.96M
Return on Assets (ROA)
-24.96%
TTM Avg
-29.43%
3Y Avg
-70.30%
5Y Avg
-70.30%
Market Cap
$857.96M
Return on Assets (ROA)
-135.59%
TTM Avg
-77.84%
3Y Avg
-48.75%
5Y Avg
-48.75%
Market Cap
$860.07M
Return on Assets (ROA)
61.78%
TTM Avg
41.06%
3Y Avg
4.27%
5Y Avg
-3.43%
Market Cap
$835.94M
Return on Assets (ROA)
-23.15%
TTM Avg
-12.59%
3Y Avg
-25.36%
5Y Avg
-32.38%
Market Cap
$861.26M
Return on Assets (ROA)
-5.88%
TTM Avg
-10.67%
3Y Avg
-19.76%
5Y Avg
-21.39%
Market Cap
$835.08M
Return on Assets (ROA)
-78.30%
TTM Avg
-72.68%
3Y Avg
-105.45%
5Y Avg
-105.45%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pacific Biosciences of California, Inc. (PACB) | $848.07M | -17.48% | -47.13% | -32.40% | -21.92% |
| QuidelOrtho Corporation (QDEL)vs › | $848.38M | -18.34% | -25.78% | -11.37% | 4.46% |
| SpyGlass Pharma, Inc. Common Stock (SGP)vs › | $842.52M | -23.03% | -34.41% | -34.41% | -34.41% |
| Beta Bionics, Inc. (BBNX)vs › | $839.96M | -24.96% | -29.43% | -70.30% | -70.30% |
| SL Science Holding Ltd (SLBT)vs › | $857.96M | -135.59% | -77.84% | -48.75% | -48.75% |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $860.07M | 61.78% | 41.06% | 4.27% | -3.43% |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $835.94M | -23.15% | -12.59% | -25.36% | -32.38% |
| SI-BONE, Inc. (SIBN)vs › | $861.26M | -5.88% | -10.67% | -19.76% | -21.39% |
| Alumis Inc. (ALMS)vs › | $835.08M | -78.30% | -72.68% | -105.45% | -105.45% |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $868.65M | -22.62% | -55.95% | -57.94% | -46.38% |
ROA
-17.5%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -69.68% |
| 2024-12-31 | -24.58% |
| 2023-12-31 | -17.57% |
| 2022-12-31 | -17.78% |
| 2021-12-31 | -9.03% |
| 2020-12-31 | 7.10% |
| 2019-12-31 | -56.85% |
| 2018-12-31 | -60.23% |
| 2017-12-31 | -63.98% |
| 2016-12-31 | -53.94% |
| 2015-12-31 | -24.18% |
| 2014-12-31 | -53.13% |
| 2013-12-31 | -58.22% |
| 2012-12-31 | -72.84% |
| 2011-12-31 | -50.11% |
| 2010-12-31 | -45.84% |
| 2009-12-31 | -86.75% |
| 2008-12-31 | -38.68% |
| 2007-12-31 | 0.00% |
